Marjan Khaleghi
Nurse Practitioner · Upland, CANPI 1952635237
Payments from drug & device makers
Across 848 payments — averaging $20.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Amgen$4K
- Johnson & Johnson$2K
- Novartis$1K
- GSK$1K
- Mallinckrodt Hospital Products Inc.$755
- plus $5K from 25 others
Across 18 payments — averaging $176.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$3K
What the payments were for
- Food & beverage$17,31099%
- Education$2541%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 192 | $4,110 |
| Amgen(2 entities) | 197 | $3,743 |
| Johnson & Johnson | 82 | $1,896 |
| Novartis | 102 | $1,439 |
| GSK | 51 | $1,005 |
| Mallinckrodt Hospital Products Inc. | 24 | $755 |
| AstraZeneca(2 entities) | 20 | $563 |
| Lilly USA, LLC | 23 | $509 |
| Pfizer | 20 | $450 |
| UCB, Inc. | 20 | $416 |
| Organon | 21 | $378 |
| Aurinia Pharma U.S., Inc. | 16 | $360 |
| Boehringer Ingelheim | 11 | $262 |
| Fresenius Kabi USA, LLC | 7 | $220 |
| E.r. Squibb & Sons, L.L.C. | 10 | $203 |
| Radius Health, Inc. | 7 | $201 |
| Kiniksa Pharmaceuticals International, PLC | 5 | $143 |
| Sobi, Inc | 6 | $141 |
| Sandoz | 5 | $104 |
| Azurity Pharmaceuticals, Inc. | 4 | $93 |
| Sanofi | 4 | $92 |
| ANI Pharmaceuticals, Inc. | 3 | $84 |
| Cumberland Pharmaceuticals, Inc. | 3 | $80 |
| Octapharma USA, Inc. | 2 | $77 |
| Scilex Pharmaceuticals Inc. | 3 | $58 |
| Alvogen Inc | 3 | $50 |
| Genentech USA, Inc. | 2 | $45 |
| Kyowa Kirin, Inc. | 2 | $33 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,564 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 53 | $522,142 |
| Enbrel SureclickEtanercept | 52 | $378,037 |
| RinvoqUpadacitinib | 23 | $221,344 |
| ProliaDenosumab | 76 | $123,620 |
| Orencia ClickjectAbatacept | 16 | $88,452 |
| Actemra ActpenTocilizumab | 17 | $60,223 |
| BenlystaBelimumab | 12 | $55,571 |
| InflectraInfliximab-Dyyb | 13 | $50,214 |
| OtrexupMethotrexate/Pf | 19 | $19,183 |
| Hydroxychloroquine Sulfate | 336 | $17,682 |
| RasuvoMethotrexate/Pf | 28 | $16,023 |
| MethotrexateMethotrexate Sodium | 263 | $7,663 |
| Fentanyl | 12 | $7,546 |
| Leflunomide | 56 | $4,010 |
| Sulfasalazine | 109 | $2,803 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $4,110 | $221,34423 claims |
| AmgenProlia | $3,743 | $123,62076 claims |
| GSKBenlysta | $1,005 | $55,57112 claims |
| PfizerInflectra | $450 | $50,21413 claims |
| Fresenius Kabi USA, LLCSodium Chloride | $220 | $1914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.
Other nurse practitioner in Upland
- Dani AchiUpland$341K
- Rhonda HewittStanford$917K
- Linda TrinhIrvine$899K
- Denise SinagaNorthridge$728K
- Debbie TaySanta Monica$642K
- Joe GorelickCampbell$638K
- Lynsey LakinArcadia$540K
- Kelly ChoiRancho Cucamonga$483K
- Hamta ZareStanford$428K
- Shawna ChrismanRoseville$425K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.